Bristol-Myers Squibb Company

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

21
Somewhat Bullish +42

Bristol Myers Squibb Company $BMY Shares Sold by Mid American Wealth Advisory Group Inc. - MarketBeat

AI-generated analysis

Bristol Myers Squibb (BMY) reported strong quarterly financial results, beating analyst expectations with earnings per share of $2.04 against a consensus of $1.60 and revenue rising 5.7% year-over-year to $12.97 billion. The company maintains a robust balance sheet with a quick ratio of 1.38 and...

Bullish Signals

  • EPS beat at $2.04 vs $1.60 consensus with 5.7% revenue growth.
  • Defensive profile offers 3.8% dividend yield on low valuation.
  • Strong liquidity shown by quick ratio of 1.38 and 18.87% net margin.
  • Upgrades from Sanford Bernstein and JPMorgan raise price target to $73.
  • New depression therapy trial expands growth into large potential market.

Bearish Signals

  • Zola-cel trials paused due to serious inflammatory side effects.
  • Revenue risks from Opdivo declines and Eliquis patent expiry.
  • Mid American Wealth reduced stake by 27.8% selling 22k shares.
  • Healthcare sector downturn adds pressure to stock performance.
  • SVP Phil Holzer sold 500 shares in late August.
22
Somewhat Bullish +45

Nykredit A S Purchases New Shares in Bristol Myers Squibb Company $BMY - MarketBeat

AI-generated analysis

Nykredit A/S purchased 506,199 shares of Bristol Myers Squibb (BMY) in the second quarter, valued at approximately $29.2 million, contributing to institutional ownership of 76.41%. The company reported strong quarterly financials with earnings per share of $2.04, beating estimates of $1.60, and revenue rising 5.7%...

Bullish Signals

  • Bristol Myers Squibb reported quarterly EPS of $2.04, beating analyst estimates of $1.60 by $0.44.
  • Revenue rose 5.7% year-over-year to $12.97 billion, exceeding the consensus estimate of $11.74 billion.
  • Encouraging long-term data for Camzyos from the EXPLORER-LTE study supports renewed investor interest and growth expectations.
  • Institutional ownership remains strong at 76.41%, with Nykredit A/S adding a $29.2 million position in Q2.
  • Analysts have upgraded or initiated coverage with bullish ratings, including 'outperform' from Sanford C. Bernstein and 'strong-buy' from Raymond James.
  • The stock trades at a P/E ratio of 14.99 with a market capitalization of $139.03 billion, reflecting solid valuation metrics.
  • Analysts forecast FY 2026 EPS between 6.75 and 7.00, indicating continued growth expectations.

Bearish Signals

  • Bristol Myers Squibb voluntarily paused enrollment in zola-cel autoimmune trials after inflammatory side effects emerged.
  • The trial pause raises concerns about the therapy's risk profile and may delay a potentially important pipeline program.
  • Broader reporting that Novartis and BMY halted autoimmune trials following deaths or serious side effects reinforces safety concerns.
  • RBC Capital maintained a 'Hold' rating, noting that the stock's strong run may already incorporate much of the favorable news.
  • Corporate insider SVP Phil M. Holzer sold 500 shares in late August, representing a 2.88% decrease in his position.
23
Bullish +55

Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval ...

AI-generated analysis

Simply Wall St analysis suggests Bristol-Myers Squibb (BMY) stock is undervalued by approximately 46.3%, trading at $63.83 per share against a Discounted Cash Flow (DCF) intrinsic value estimate of roughly $119. The company has delivered a 38.1% gain over the past year, yet valuation metrics...

Bullish Signals

  • 38.1% gain over past year.
  • FDA approved ZENBEXUS asset.
  • $2.3B Houston manufacturing campus.
  • P/E 14.0x vs industry 16.9x.
  • Fair P/E 18.2x implies discount.

Bearish Signals

  • Revived lawsuit exposes company to ~US$6.7 billion financial risk.
  • Patent cliffs for Eliquis (2028) and Opdivo raise generic competition risks.
  • Conservative DCF model limits upside if growth falls short of expectations.
24
Bullish +55

Janney Montgomery Scott LLC Purchases 49,310 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

AI-generated analysis

Janney Montgomery Scott LLC increased its stake in Bristol Myers Squibb (NYSE:BMY) by 6.8% in the first quarter, purchasing 49,310 shares to bring total holdings to 770,244 shares valued at approximately $46.7 million. Other institutional investors also adjusted positions, with Horizon Bancorp increasing its stake...

Bullish Signals

  • EPS beat estimates at $1.58 vs $1.42 consensus.
  • Revenue hit $11.49B, up 2.6% year-over-year.
  • Institutional confidence rises as Janney adds 6.8% position.
  • Wall Street Zen upgrades rating to strong-buy.
  • HSBC raises price target from $53 to $60.
  • Quarterly dividend of $0.63 offers 4.4% yield.

Bearish Signals

  • David V. Elkins sold 30,000 shares, reducing stake by 15.85%.
  • Bank of America lowered price objective from $68.00 to $67.00.
  • Citigroup reissued neutral rating on the stock.
  • Consensus analyst rating is Hold with limited upside potential.
25
Somewhat Bullish +50

Bristol Myers Squibb Q1 Earnings Call Highlights

AI-generated analysis

Bristol Myers Squibb reported solid first-quarter results with total revenue of approximately $11.5 billion, representing a 1% year-over-year increase, while its growth portfolio expanded by 9% to reach $6.2 billion. Key performers included Breyanzi, which grew 53%, and Camzyos, whose revenue nearly doubled to $314...

Bullish Signals

  • Bristol Myers Squibb delivered solid Q1 results with total revenue of approximately $11.5 billion, marking a 1% year-over-year increase.
  • The growth portfolio increased by 9% to $6.2 billion, demonstrating strong momentum in high-potential product lines.
  • Breyanzi revenue grew 53%, attributed to its best-in-class profile and demand across approved indications in the U.S. and international markets.
  • Camzyos revenue nearly doubled to $314 million, driven by continued global demand for the heart condition treatment.
  • Eliquis revenue increased 13% to approximately $4.1 billion, reflecting strong underlying demand despite recent price reductions.
  • Reblozyl grew 15%, showing continued uptake in first- and second-line treatments for MDS-associated anemia.
  • Sotyktu achieved a 20% global growth rate following its recent approval in psoriatic arthritis, with positive potential in lupus and Sjögren's disease pipelines.
  • Opdualag posted another quarter of double-digit growth, reinforced by global demand and its status as the standard of care in first-line melanoma treatment.
  • The company secured major regulatory milestones, including FDA acceptance of iberdomide for multiple myeloma with breakthrough therapy designation and a PDUFA date of Aug. 17.
  • Management highlighted positive phase III interim data for mezigdomide, which demonstrated meaningful improvement in progression-free survival.
  • Bristol Myers Squibb reaffirmed its full-year 2026 guidance, tracking toward the upper end of established ranges, signaling management confidence.
  • The company ended March with a robust $11 billion in cash equivalents and marketable securities while maintaining disciplined capital allocation.

Bearish Signals

  • Opdivo revenue declined 8% to $2.1 billion, driven by a U.S. wholesaler inventory drawdown with levels at the low end of the typical range.
  • Eliquis collections were negatively impacted by a U.S. price reduction implemented at the start of the year and increased generic entry across several other brands.
  • Gross margins contracted 280 basis points to 70.3%, primarily due to product mix shifts rather than operational efficiency gains.
  • Operating expenses rose slightly above the prior-year period at $3.9 billion, partly due to incremental investments in new drug candidates.
  • The company recorded a net $0.03 per-share charge related to in-process R&D and licensing income which impacted diluted EPS of $1.58.
  • Cash collections were down approximately $1.2 billion quarter-over-quarter tied to the Eliquis list price reductions, creating near-term headwinds for cash flow.
  • Management reaffirmed full-year 2026 guidance while pursuing productivity savings, indicating ongoing pressure to manage costs and margins amidst growth investments.